Review anchor
Trifunctional purine biosynthetic protein adenosine-3
SINGLE PROTEIN · Mus musculus
As of 2026-09-14
Evidence Snapshot
Trifunctional purine biosynthetic protein adenosine-3
CHEMBL3690
SINGLE PROTEIN
Mus musculus
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Trifunctional purine biosynthetic protein adenosine-3 as ChEMBL target CHEMBL3690, mapped to UniProt Q64737. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL3690
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q64737
Trifunctional purine biosynthetic protein adenosine-3
UniProt accession via ChEMBL component mapping
As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-14
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Trifunctional purine biosynthetic protein adenosine-3 matters
Trifunctional purine biosynthetic protein adenosine-3 is reviewed as Trifunctional purine biosynthetic protein adenosine-3 (UniProt Q64737); the current evidence base includes 0 approved drugs, 51 compounds, and 26 assays, with lead potency reaching pChEMBL 10.7.
Protein context
Trifunctional purine biosynthetic protein adenosine-3
Trifunctional purine biosynthetic protein adenosine-3 Sequence length is 1010 aa.
Review this target as Trifunctional purine biosynthetic protein adenosine-3, mapped to UniProt Q64737. Sequence length is 1010 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q64737
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 0 approved drugs, 51 compounds, and 26 assays for this target. The dominant activity type is IC50. CHEMBL279302 is the current potency anchor at pChEMBL 10.7.
Use CHEMBL279302 as the tractability anchor when discussing potency (pChEMBL 10.7).
Activity source · ChEMBL 36 via Core Engine
pChEMBL 10.7
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Trifunctional purine biosynthetic protein adenosine-3 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q64737, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
51
Total Compounds
26
Total Assays
0
Approved Drugs
IC50: 39.0, KI: 29.0, KD: 1.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL279302
|
10.7 | IC50 | — |
|
|
No preferred name
CHEMBL607957
|
9.6 | Kd | — |
|
|
No preferred name
CHEMBL267890
|
8.0 | IC50 | — |
|
|
No preferred name
CHEMBL38902
|
7.3 | Ki | — |
|
|
No preferred name
CHEMBL34412
|
7.2 | Ki | Clinical |
Source Header